Dr. Reddy’s has launched Toripalimab in India: Advancing Treatment for Nasopharyngeal Carcinoma
https://oncodaily.com/insight/194236
##Cancer ##Cisplatin ##EMA ##Gemcitabine ##MHRA ##Nasopharyngeal ##Carcinoma ##NMPA ##OncoDaily ##Oncology ##ReddysLaboratories ##BiosciencesCo ##Toripalimab ##USFDA
https://oncodaily.com/insight/194236
##Cancer ##Cisplatin ##EMA ##Gemcitabine ##MHRA ##Nasopharyngeal ##Carcinoma ##NMPA ##OncoDaily ##Oncology ##ReddysLaboratories ##BiosciencesCo ##Toripalimab ##USFDA
Dr. Reddy’s has launched Toripalimab in India: Advancing Treatment for Nasopharyngeal Carcinoma - OncoDaily
Dr. Reddy’s has launched Toripalimab in India: Advancing Treatment for Nasopharyngeal Carcinoma / cancer, Cisplatin, EMA, Gemcitabine, M.V. Ramana, MHRA,
oncodaily.com
December 2, 2024 at 11:00 PM
Dr. Reddy’s has launched Toripalimab in India: Advancing Treatment for Nasopharyngeal Carcinoma
https://oncodaily.com/insight/194236
##Cancer ##Cisplatin ##EMA ##Gemcitabine ##MHRA ##Nasopharyngeal ##Carcinoma ##NMPA ##OncoDaily ##Oncology ##ReddysLaboratories ##BiosciencesCo ##Toripalimab ##USFDA
https://oncodaily.com/insight/194236
##Cancer ##Cisplatin ##EMA ##Gemcitabine ##MHRA ##Nasopharyngeal ##Carcinoma ##NMPA ##OncoDaily ##Oncology ##ReddysLaboratories ##BiosciencesCo ##Toripalimab ##USFDA
Cisplatin in Cancer Treatment: Mechanism, Resistance, Toxicity, and Future Directions
oncodaily.com/drugs/cispla...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Cisplatin #Immunotherapy #Mechanism #Pharmacology #Resistance #Toxicity
oncodaily.com/drugs/cispla...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Cisplatin #Immunotherapy #Mechanism #Pharmacology #Resistance #Toxicity
Cisplatin in Cancer Treatment: Mechanism, Resistance, Toxicity, and Future Directions - OncoDaily
Explore how cisplatin, a cornerstone platinum-based chemotherapy, works to treat cancer. Learn about its mechanism of action, clinical applications, resistance pathways, side effects, and future direc...
oncodaily.com
July 10, 2025 at 6:38 PM
Cisplatin in Cancer Treatment: Mechanism, Resistance, Toxicity, and Future Directions
oncodaily.com/drugs/cispla...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Cisplatin #Immunotherapy #Mechanism #Pharmacology #Resistance #Toxicity
oncodaily.com/drugs/cispla...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Cisplatin #Immunotherapy #Mechanism #Pharmacology #Resistance #Toxicity
Please join us for the Jeff Agar's presentation at Proteoform Thursday March 20 - "Intact Mass Assay Determines Covalent Drug-Target Binding and PK/PD Parameters” #proteomics #ALS #Cisplatin us06web.zoom.us/meeting/regi...
March 7, 2025 at 8:20 PM
Please join us for the Jeff Agar's presentation at Proteoform Thursday March 20 - "Intact Mass Assay Determines Covalent Drug-Target Binding and PK/PD Parameters” #proteomics #ALS #Cisplatin us06web.zoom.us/meeting/regi...
#IntravitalImaging #PeritubularMicrocirculation #Cisplatin 🐭 #AcuteKidneyInjury
2 mD FITC-dextran DiD-RBC▶️vessel
4 kD TMR-dextran▶️tubule
Microvascular failure precedes renal damage biomarker
CD11b Ab➡️inhibit myeloid cells➡️rescue flow
@jci-insight.bsky.social 2025
insight.jci.org/articles/vie...
2 mD FITC-dextran DiD-RBC▶️vessel
4 kD TMR-dextran▶️tubule
Microvascular failure precedes renal damage biomarker
CD11b Ab➡️inhibit myeloid cells➡️rescue flow
@jci-insight.bsky.social 2025
insight.jci.org/articles/vie...
April 14, 2025 at 11:45 AM
#IntravitalImaging #PeritubularMicrocirculation #Cisplatin 🐭 #AcuteKidneyInjury
2 mD FITC-dextran DiD-RBC▶️vessel
4 kD TMR-dextran▶️tubule
Microvascular failure precedes renal damage biomarker
CD11b Ab➡️inhibit myeloid cells➡️rescue flow
@jci-insight.bsky.social 2025
insight.jci.org/articles/vie...
2 mD FITC-dextran DiD-RBC▶️vessel
4 kD TMR-dextran▶️tubule
Microvascular failure precedes renal damage biomarker
CD11b Ab➡️inhibit myeloid cells➡️rescue flow
@jci-insight.bsky.social 2025
insight.jci.org/articles/vie...
Early and Sensitive Detection of #Cisplatin Induced #KidneyInjury Using Novel #Biomarkers
#VisualAbstract by @jmteakell
www.kireports.org/ar...
#VisualAbstract by @jmteakell
www.kireports.org/ar...
February 27, 2025 at 11:00 PM
Early and Sensitive Detection of #Cisplatin Induced #KidneyInjury Using Novel #Biomarkers
#VisualAbstract by @jmteakell
www.kireports.org/ar...
#VisualAbstract by @jmteakell
www.kireports.org/ar...
Repression of peroxisome proliferation-activated receptor γ coactivator-1α by p53 after #kidneyinjury promotes mitochondrial damage and maladaptive #kidney repair
doi.org/10.1016/j.kint.2025.02.009
#MedSky #NephSky #renalfibrosis #kidneyfibrosis #cisplatin #aki #acutekidneyinjury
doi.org/10.1016/j.kint.2025.02.009
#MedSky #NephSky #renalfibrosis #kidneyfibrosis #cisplatin #aki #acutekidneyinjury
March 10, 2025 at 6:28 PM
Repression of peroxisome proliferation-activated receptor γ coactivator-1α by p53 after #kidneyinjury promotes mitochondrial damage and maladaptive #kidney repair
doi.org/10.1016/j.kint.2025.02.009
#MedSky #NephSky #renalfibrosis #kidneyfibrosis #cisplatin #aki #acutekidneyinjury
doi.org/10.1016/j.kint.2025.02.009
#MedSky #NephSky #renalfibrosis #kidneyfibrosis #cisplatin #aki #acutekidneyinjury
#YangheDecoction suppresses #Osteosarcoma progression by inducing #ROS-mediated mitochondrial dysfunction, inhibiting PI3K/AKT signaling, activating p38 MAPK, & enhancing #cisplatin sensitivity, highlighting its potential as an adjuvant #CancerTherapy.
Read: doi.org/10.1016/j.ge...
Read: doi.org/10.1016/j.ge...
May 19, 2026 at 5:10 PM
#YangheDecoction suppresses #Osteosarcoma progression by inducing #ROS-mediated mitochondrial dysfunction, inhibiting PI3K/AKT signaling, activating p38 MAPK, & enhancing #cisplatin sensitivity, highlighting its potential as an adjuvant #CancerTherapy.
Read: doi.org/10.1016/j.ge...
Read: doi.org/10.1016/j.ge...
🚀 Key #UrothelialCancer abstracts from #ASCOGU!
📌 Abstract 661 – #Durvalumab (#MEDI4736) + neoadjuvant chemo (#Gemcitabine + #Cisplatin / #Carboplatin) in high-risk upper tract urothelial carcinoma.
📌 Abstract 667 – #Durvalumab + intravesical #Gemcitabine & #Docetaxel in #BCG-unresponsive NMIBC.
📌 Abstract 661 – #Durvalumab (#MEDI4736) + neoadjuvant chemo (#Gemcitabine + #Cisplatin / #Carboplatin) in high-risk upper tract urothelial carcinoma.
📌 Abstract 667 – #Durvalumab + intravesical #Gemcitabine & #Docetaxel in #BCG-unresponsive NMIBC.
February 8, 2025 at 9:29 AM
🚀 Key #UrothelialCancer abstracts from #ASCOGU!
📌 Abstract 661 – #Durvalumab (#MEDI4736) + neoadjuvant chemo (#Gemcitabine + #Cisplatin / #Carboplatin) in high-risk upper tract urothelial carcinoma.
📌 Abstract 667 – #Durvalumab + intravesical #Gemcitabine & #Docetaxel in #BCG-unresponsive NMIBC.
📌 Abstract 661 – #Durvalumab (#MEDI4736) + neoadjuvant chemo (#Gemcitabine + #Cisplatin / #Carboplatin) in high-risk upper tract urothelial carcinoma.
📌 Abstract 667 – #Durvalumab + intravesical #Gemcitabine & #Docetaxel in #BCG-unresponsive NMIBC.
Etwa jede siebte an #Krebs erkrankte Person entwickelt nach einer #Cisplatin-Therapie eine chronische #Nierenerkrankung. Forschende haben nun analysiert, wovon das Risiko abhängt. Ein einfaches Modell könne demnach die klinische Entscheidungsfindung verbessern. #MedSky #Medizin
Cisplatin – mit der eGFR das Risiko für die Nieren abschätzen
Kanadische Analyse
www.springermedizin.de
August 29, 2025 at 1:37 PM
Etwa jede siebte an #Krebs erkrankte Person entwickelt nach einer #Cisplatin-Therapie eine chronische #Nierenerkrankung. Forschende haben nun analysiert, wovon das Risiko abhängt. Ein einfaches Modell könne demnach die klinische Entscheidungsfindung verbessern. #MedSky #Medizin
Drug Shortages Continue to Threaten People with Cancer www.peoplespharmacy.com/articles/dru... via @peoplespharmacy
#drugshortages #cancer #cisplatin #carboplatin #ifosfamide #health
#drugshortages #cancer #cisplatin #carboplatin #ifosfamide #health
Drug Shortages Continue to Threaten People with Cancer
Generic drug companies have let us down again. Critical drug shortages of cisplatin, carboplatin and ifosfamide are scary for cancer patients
www.peoplespharmacy.com
July 7, 2026 at 1:15 PM
Drug Shortages Continue to Threaten People with Cancer www.peoplespharmacy.com/articles/dru... via @peoplespharmacy
#drugshortages #cancer #cisplatin #carboplatin #ifosfamide #health
#drugshortages #cancer #cisplatin #carboplatin #ifosfamide #health
Norgine Celebrates TGA Approval for PEDMARQSI® to Prevent Hearing Loss in Young Cancer Patients#Australia#Amsterdam#Norgine#CISPLATIN#PEDMARQSI®
Norgine Celebrates TGA Approval for PEDMARQSI® to Prevent Hearing Loss in Young Cancer Patients
Norgine proudly announces the TGA registration of PEDMARQSI®, a breakthrough treatment designed to prevent cisplatin-induced hearing loss in children, marking a significant advance in pediatric oncology care.
third-news.com
May 5, 2026 at 9:29 PM
Norgine Celebrates TGA Approval for PEDMARQSI® to Prevent Hearing Loss in Young Cancer Patients#Australia#Amsterdam#Norgine#CISPLATIN#PEDMARQSI®
Norgine Celebrates TGA Approval of PEDMARQSI® for Children in Australia#Australia#Amsterdam#Norgine#CISPLATIN#PEDMARQSI
Norgine Celebrates TGA Approval of PEDMARQSI® for Children in Australia
Norgine has announced the TGA's approval of PEDMARQSI® in Australia, a groundbreaking treatment for preventing cisplatin-induced hearing loss in children undergoing chemotherapy.
third-news.com
May 5, 2026 at 9:08 PM
Norgine Celebrates TGA Approval of PEDMARQSI® for Children in Australia#Australia#Amsterdam#Norgine#CISPLATIN#PEDMARQSI
Norgine Celebrates TGA Approval of PEDMARQSI® for Preventing Hearing Loss in Children#Australia#Amsterdam#Norgine#CISPLATIN#PEDMARQSI
Norgine Celebrates TGA Approval of PEDMARQSI® for Preventing Hearing Loss in Children
Norgine announces the TGA registration of PEDMARQSI®, a new treatment to prevent hearing loss caused by cisplatin in children, providing hope for many families.
third-news.com
May 5, 2026 at 9:06 PM
Norgine Celebrates TGA Approval of PEDMARQSI® for Preventing Hearing Loss in Children#Australia#Amsterdam#Norgine#CISPLATIN#PEDMARQSI
October Issue: Conversion to Resection After Neoadjuvant #Gemcitabine , #Cisplatin , and #NabPaclitaxel for Borderline Resectable CCA: A Real-World Exploratory Analysis
https://rdcu.be/eMq0E
https://rdcu.be/eMq0E
October 24, 2025 at 4:02 PM
October Issue: Conversion to Resection After Neoadjuvant #Gemcitabine , #Cisplatin , and #NabPaclitaxel for Borderline Resectable CCA: A Real-World Exploratory Analysis
https://rdcu.be/eMq0E
https://rdcu.be/eMq0E
This latest study shows that Yanghe Decoction suppresses #Osteosarcoma (OS) cell processes by inducing #Apoptosis, #MitochondrialDysfunction & boosting #cisplatin sensitivity, promising synergistic approaches to OS treatment. #medsky
#OpenAccess: www.sciencedirect.com/science/arti...
#OpenAccess: www.sciencedirect.com/science/arti...
October 12, 2025 at 2:30 PM
This latest study shows that Yanghe Decoction suppresses #Osteosarcoma (OS) cell processes by inducing #Apoptosis, #MitochondrialDysfunction & boosting #cisplatin sensitivity, promising synergistic approaches to OS treatment. #medsky
#OpenAccess: www.sciencedirect.com/science/arti...
#OpenAccess: www.sciencedirect.com/science/arti...
Can #IntermittentFasting boost #Cisplatin + #Metformin in resistant #OvarianCancer? 🍽️🧬 This new #iScience paper shows it improves response & survival by stressing #CancerMetabolism 🧠💪
🧾 www.cell.com/action/showP...
🧾 www.cell.com/action/showP...
January 12, 2026 at 5:05 PM
Can #IntermittentFasting boost #Cisplatin + #Metformin in resistant #OvarianCancer? 🍽️🧬 This new #iScience paper shows it improves response & survival by stressing #CancerMetabolism 🧠💪
🧾 www.cell.com/action/showP...
🧾 www.cell.com/action/showP...
The NCCN templates are not hugely prescriptive but for a 75mg/m² regime I just checked, they say 1-3L hydration but only suggest 4mmol (1g) per L.
I'm always surprised US doctors are not sued more.
#OncoPharm #Cisplatin #Magnesium
I'm always surprised US doctors are not sued more.
#OncoPharm #Cisplatin #Magnesium
April 24, 2025 at 10:04 PM
The NCCN templates are not hugely prescriptive but for a 75mg/m² regime I just checked, they say 1-3L hydration but only suggest 4mmol (1g) per L.
I'm always surprised US doctors are not sued more.
#OncoPharm #Cisplatin #Magnesium
I'm always surprised US doctors are not sued more.
#OncoPharm #Cisplatin #Magnesium
🆕Does exist statistically significant difference between cisplatin- and carboplatin-based CT-IT in #lungcancer❓
Learn more on this systematic review providing separate outcome data for #carboplatin and #cisplatin.
🔗 journals.sagepub.com/share/55FYJI...
#canSky #OncoSky
Learn more on this systematic review providing separate outcome data for #carboplatin and #cisplatin.
🔗 journals.sagepub.com/share/55FYJI...
#canSky #OncoSky
August 3, 2026 at 10:00 AM
🆕Does exist statistically significant difference between cisplatin- and carboplatin-based CT-IT in #lungcancer❓
Learn more on this systematic review providing separate outcome data for #carboplatin and #cisplatin.
🔗 journals.sagepub.com/share/55FYJI...
#canSky #OncoSky
Learn more on this systematic review providing separate outcome data for #carboplatin and #cisplatin.
🔗 journals.sagepub.com/share/55FYJI...
#canSky #OncoSky
@ILCAnews breakthrough in #CCA May be combo cytolytic/ICC combo #gemcitabin #cisplatin #durvalumab which appears to offer OS and PFS benefit
December 2, 2024 at 11:56 PM
@ILCAnews breakthrough in #CCA May be combo cytolytic/ICC combo #gemcitabin #cisplatin #durvalumab which appears to offer OS and PFS benefit
FDA approves pembrolizumab (Keytruda) with enfortumab vedotin-ejfv (Padcev) as a new neoadjuvant and adjuvant option for adults with muscle-invasive bladder cancer who can’t receive #cisplatin. #TCSC #CancerNews #BladderCancer #Immunotherapy #FDA
www.fda.gov/drugs/resour...
www.fda.gov/drugs/resour...
FDA approves pembrolizumab with enfortumab vedotin-ejfv
On November 21, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex,
www.fda.gov
November 22, 2025 at 11:19 AM
FDA approves pembrolizumab (Keytruda) with enfortumab vedotin-ejfv (Padcev) as a new neoadjuvant and adjuvant option for adults with muscle-invasive bladder cancer who can’t receive #cisplatin. #TCSC #CancerNews #BladderCancer #Immunotherapy #FDA
www.fda.gov/drugs/resour...
www.fda.gov/drugs/resour...
A new study from Cedars-Sinai Cancer and the University of Colorado Anschutz Medical Campus reveals a potential way to overcome tumour resistance to a common chemotherapy drug called cisplatin.#TCSC #cisplatin #chemotherapy
www.cancerhealth.com/article/canc...
www.cancerhealth.com/article/canc...
Combating Chemotherapy Resistance in Cancer
Study reveals opportunities to improve effectiveness of common chemotherapy drug
www.cancerhealth.com
January 3, 2025 at 7:37 AM
A new study from Cedars-Sinai Cancer and the University of Colorado Anschutz Medical Campus reveals a potential way to overcome tumour resistance to a common chemotherapy drug called cisplatin.#TCSC #cisplatin #chemotherapy
www.cancerhealth.com/article/canc...
www.cancerhealth.com/article/canc...
creates semantic nodes and clusters
#AWBRIDGE F C
aepiot.ro/advanced-sea...
#CISPLATIN
semantic-search.allgraph.ro/advanced-sea...
AÉPIOT: INDEPENDENT SEMANTIC WEB 4.0 INFRASTRUCTURE (EST. 2009): aepiot.com
#AWBRIDGE F C
aepiot.ro/advanced-sea...
#CISPLATIN
semantic-search.allgraph.ro/advanced-sea...
AÉPIOT: INDEPENDENT SEMANTIC WEB 4.0 INFRASTRUCTURE (EST. 2009): aepiot.com
MultiSearch Tag Explorer
MultiSearch Tag Explorer - Explore tags and search results by aéPiot - aéPiot: Independent SEMANTIC Web 4.0 Infrastructure (Est. 2009). High-density Functional Semantic Connectivity with 100/100 Trust...
aepiot.ro
May 12, 2026 at 8:48 AM
creates semantic nodes and clusters
#AWBRIDGE F C
aepiot.ro/advanced-sea...
#CISPLATIN
semantic-search.allgraph.ro/advanced-sea...
AÉPIOT: INDEPENDENT SEMANTIC WEB 4.0 INFRASTRUCTURE (EST. 2009): aepiot.com
#AWBRIDGE F C
aepiot.ro/advanced-sea...
#CISPLATIN
semantic-search.allgraph.ro/advanced-sea...
AÉPIOT: INDEPENDENT SEMANTIC WEB 4.0 INFRASTRUCTURE (EST. 2009): aepiot.com
MSU will receive a 2025 Golden Goose Award for the scientific success and global impact of cisplatin. To read more, click here: innovationcenter.msu.edu/msus-cisplat...
#Cisplatin #CancerResearch #MSU #GoldenGooseAward #ScientificDiscovery #HealthcareInnovation #CuriosityDrivenResearch
#Cisplatin #CancerResearch #MSU #GoldenGooseAward #ScientificDiscovery #HealthcareInnovation #CuriosityDrivenResearch
September 24, 2025 at 1:26 AM
MSU will receive a 2025 Golden Goose Award for the scientific success and global impact of cisplatin. To read more, click here: innovationcenter.msu.edu/msus-cisplat...
#Cisplatin #CancerResearch #MSU #GoldenGooseAward #ScientificDiscovery #HealthcareInnovation #CuriosityDrivenResearch
#Cisplatin #CancerResearch #MSU #GoldenGooseAward #ScientificDiscovery #HealthcareInnovation #CuriosityDrivenResearch
Hey #cancer cells! KI's Lippard Lab says resistance to #cisplatin is futile. They're so #metal.via @MITnews)
mitne.ws/1aZLUkF
mitne.ws/1aZLUkF
February 7, 2025 at 6:11 PM
Hey #cancer cells! KI's Lippard Lab says resistance to #cisplatin is futile. They're so #metal.via @MITnews)
mitne.ws/1aZLUkF
mitne.ws/1aZLUkF